JP2018514589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514589A5 JP2018514589A5 JP2018507796A JP2018507796A JP2018514589A5 JP 2018514589 A5 JP2018514589 A5 JP 2018514589A5 JP 2018507796 A JP2018507796 A JP 2018507796A JP 2018507796 A JP2018507796 A JP 2018507796A JP 2018514589 A5 JP2018514589 A5 JP 2018514589A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- pharmaceutical composition
- cannabinoid
- thc
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930003827 cannabinoid Natural products 0.000 claims description 56
- 239000003557 cannabinoid Substances 0.000 claims description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims description 56
- 150000003839 salts Chemical class 0.000 claims description 55
- 230000001225 therapeutic effect Effects 0.000 claims description 27
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 238000011287 therapeutic dose Methods 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 230000009286 beneficial effect Effects 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- -1 palmitoyl cyclohexaneamide Chemical compound 0.000 claims description 3
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims 8
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 8
- 229960004242 dronabinol Drugs 0.000 claims 8
- 208000000323 Tourette Syndrome Diseases 0.000 claims 6
- 208000016620 Tourette disease Diseases 0.000 claims 6
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical group CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- KASVLYINZPAMNS-UHFFFAOYSA-N Cannabigerol monomethylether Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(OC)=C1 KASVLYINZPAMNS-UHFFFAOYSA-N 0.000 claims 2
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 claims 2
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 2
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 2
- 229950011318 cannabidiol Drugs 0.000 claims 2
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 2
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 claims 1
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- IGHTZQUIFGUJTG-QSMXQIJUSA-N O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 Chemical compound O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 IGHTZQUIFGUJTG-QSMXQIJUSA-N 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims 1
- 206010021654 increased appetite Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- TZYVUGCYYQOTQR-UHFFFAOYSA-N n-propan-2-ylhexadecanamide Chemical compound CCCCCCCCCCCCCCCC(=O)NC(C)C TZYVUGCYYQOTQR-UHFFFAOYSA-N 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229950007031 palmidrol Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000218236 Cannabis Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- PVCJKHHOXFKFRP-UHFFFAOYSA-N N-acetylethanolamine Chemical compound CC(=O)NCCO PVCJKHHOXFKFRP-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021057991A JP2021107401A (ja) | 2015-04-29 | 2021-03-30 | カンナビノイドとｎ−アシルエタノールアミンの組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154144P | 2015-04-29 | 2015-04-29 | |
| US62/154,144 | 2015-04-29 | ||
| PCT/IL2016/050414 WO2016174661A1 (en) | 2015-04-29 | 2016-04-19 | Combinations of cannabinoids and n-acylethanolamines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021057991A Division JP2021107401A (ja) | 2015-04-29 | 2021-03-30 | カンナビノイドとｎ−アシルエタノールアミンの組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514589A JP2018514589A (ja) | 2018-06-07 |
| JP2018514589A5 true JP2018514589A5 (cg-RX-API-DMAC10.html) | 2019-05-30 |
| JP6938465B2 JP6938465B2 (ja) | 2021-09-22 |
Family
ID=57199061
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507796A Active JP6938465B2 (ja) | 2015-04-29 | 2016-04-19 | カンナビノイドとｎ−アシルエタノールアミンの組み合わせ |
| JP2021057991A Pending JP2021107401A (ja) | 2015-04-29 | 2021-03-30 | カンナビノイドとｎ−アシルエタノールアミンの組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021057991A Pending JP2021107401A (ja) | 2015-04-29 | 2021-03-30 | カンナビノイドとｎ−アシルエタノールアミンの組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US11234956B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4193993A3 (cg-RX-API-DMAC10.html) |
| JP (2) | JP6938465B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN107530317A (cg-RX-API-DMAC10.html) |
| AU (4) | AU2016254685B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2984088C (cg-RX-API-DMAC10.html) |
| DK (1) | DK3288553T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2935605T3 (cg-RX-API-DMAC10.html) |
| IL (2) | IL291864A (cg-RX-API-DMAC10.html) |
| MA (1) | MA41997A (cg-RX-API-DMAC10.html) |
| PL (1) | PL3288553T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2016174661A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11234956B2 (en) * | 2015-04-29 | 2022-02-01 | SciSparc Ltd. | Combination of cannabinoids and n-acylethanolamines |
| US20210052478A1 (en) * | 2018-01-05 | 2021-02-25 | Altus Labs, Llc | Personal care compositions |
| US20220000833A1 (en) * | 2018-01-29 | 2022-01-06 | Therapix Biosciences Ltd. | Compositions and methods for treating obstructive sleep apnea |
| US11951086B2 (en) * | 2018-04-03 | 2024-04-09 | Pure Green Pharmaceuticals, Inc. | Tablet or composition having n-acyl ethanolamine and cannabinoid |
| WO2020160452A1 (en) * | 2019-02-01 | 2020-08-06 | Tess Ventures, Inc. | Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies |
| AU2020260090C9 (en) | 2019-04-15 | 2023-08-31 | Metagenics LLC | Novel hemp and PEA formulation and its use |
| EP3958850A4 (en) * | 2019-04-23 | 2023-04-26 | Scisparc Ltd. | COMPOSITIONS AND METHODS FOR POTENTIALIZING 4-AMINOPHENOL DERIVATIVES |
| EP3965789A4 (en) * | 2019-05-07 | 2023-01-25 | Ojai Energetics PBC | PROCEDURE FOR OPTIMIZING CANNABINOID DOSAGE DETERMINATION |
| WO2020237247A1 (en) | 2019-05-23 | 2020-11-26 | India Globalization Capital, Inc. | Compositions and methods using cannabinoids for treating stammering/stutering and symptoms of tourette syndrome |
| EP4017486A4 (en) * | 2019-08-19 | 2023-09-20 | Buzzelet Development And Technologies Ltd | COMPOSITIONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND THEIR USES |
| EP3838346A1 (en) * | 2019-12-20 | 2021-06-23 | Chemo Research SL | Soft gelatin capsules comprising palmitoylethanolamide and alpha-lipoic acid |
| WO2021141959A1 (en) | 2020-01-10 | 2021-07-15 | Pacira Pharmaceuticals, Inc. | Treatment of pain by administration of sustained-release liposomal anesthetic compositions |
| CN115297854A (zh) | 2020-01-10 | 2022-11-04 | 帕西拉制药股份有限公司 | 通过蛛网膜下腔给予缓释脂质体麻醉组合物治疗疼痛 |
| US11273122B2 (en) | 2020-02-11 | 2022-03-15 | Therese Mainella | Combination of cannabis, derivatives thereof and additives in oral care compositions |
| WO2022150708A1 (en) * | 2021-01-11 | 2022-07-14 | Pacira Pharmaceuticals, Inc. | Treatment of hip pain with sustained-release liposomal anesthetic compositions |
| US20230000936A1 (en) * | 2021-06-30 | 2023-01-05 | Demetrix, Inc. | Alleviation of itching sensations using cannabinoid compounds |
| WO2023039419A2 (en) | 2021-09-08 | 2023-03-16 | Plantible Foods Inc. | Systems and methods for measuring mat density of aquatic biomass |
| US12036228B2 (en) | 2022-04-12 | 2024-07-16 | Shackelford Pharma Inc. | Treatment of seizure disorders |
| US11918565B1 (en) | 2022-11-03 | 2024-03-05 | Pacira Pharmaceuticals, Inc. | Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions |
| US12226610B2 (en) | 2022-11-03 | 2025-02-18 | Pacira Pharmaceuticals, Inc. | Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions |
| WO2024124354A1 (en) * | 2022-12-16 | 2024-06-20 | Aima Inc. | Compositions and methods for treating or preventing pain or other disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU776414B2 (en) * | 1998-05-29 | 2004-09-09 | Neurosciences Research Foundation, Inc. | Control of pain with endogenous cannabinoids |
| US6949582B1 (en) * | 1999-05-27 | 2005-09-27 | Wallace Walter H | Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment |
| GB2394894B (en) * | 2002-11-04 | 2005-08-31 | G W Pharma Ltd | New use for pharmaceutical composition |
| WO2007006319A2 (en) | 2005-07-14 | 2007-01-18 | Rheoscience A/S | Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders |
| GB2432312A (en) * | 2005-11-01 | 2007-05-23 | Gw Pharma Ltd | Pharmaceutical compositions for the treatment of pain |
| BRPI0919753B8 (pt) * | 2009-09-07 | 2021-05-25 | Epitech Group Srl | forma polimórfica de palmitoiletanolamida, composição farmacêutica para uso humano ou veterinário, método para a micronização da palmitoiletanolamida e palmitoiletanolamida ultramicronizada |
| AT509000B1 (de) * | 2009-10-23 | 2012-12-15 | Rausch Peter | Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen |
| GB2495118B (en) * | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| EP2719375A1 (en) * | 2012-10-10 | 2014-04-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms |
| US11234956B2 (en) * | 2015-04-29 | 2022-02-01 | SciSparc Ltd. | Combination of cannabinoids and n-acylethanolamines |
-
2016
- 2016-04-19 US US15/570,118 patent/US11234956B2/en active Active
- 2016-04-19 AU AU2016254685A patent/AU2016254685B2/en active Active
- 2016-04-19 PL PL16786064.2T patent/PL3288553T3/pl unknown
- 2016-04-19 CN CN201680024534.5A patent/CN107530317A/zh active Pending
- 2016-04-19 IL IL291864A patent/IL291864A/en unknown
- 2016-04-19 DK DK16786064.2T patent/DK3288553T3/da active
- 2016-04-19 MA MA041997A patent/MA41997A/fr unknown
- 2016-04-19 WO PCT/IL2016/050414 patent/WO2016174661A1/en not_active Ceased
- 2016-04-19 EP EP22215663.0A patent/EP4193993A3/en active Pending
- 2016-04-19 CA CA2984088A patent/CA2984088C/en active Active
- 2016-04-19 CN CN202310678191.6A patent/CN116549437A/zh active Pending
- 2016-04-19 ES ES16786064T patent/ES2935605T3/es active Active
- 2016-04-19 JP JP2018507796A patent/JP6938465B2/ja active Active
- 2016-04-19 EP EP16786064.2A patent/EP3288553B1/en active Active
-
2017
- 2017-10-24 IL IL255238A patent/IL255238B/en unknown
-
2019
- 2019-08-30 US US16/557,379 patent/US11207290B2/en not_active Expired - Fee Related
- 2019-10-01 US US16/589,611 patent/US20200030281A1/en not_active Abandoned
- 2019-10-10 US US16/598,029 patent/US11197845B2/en not_active Expired - Fee Related
-
2021
- 2021-03-30 JP JP2021057991A patent/JP2021107401A/ja active Pending
- 2021-07-19 AU AU2021206784A patent/AU2021206784B2/en active Active
- 2021-08-27 US US17/459,583 patent/US20210393577A1/en active Pending
- 2021-11-12 US US17/524,942 patent/US20220071948A1/en not_active Abandoned
- 2021-11-12 US US17/525,046 patent/US20220071949A1/en active Pending
-
2023
- 2023-10-17 AU AU2023251426A patent/AU2023251426B2/en active Active
-
2025
- 2025-12-31 AU AU2025287414A patent/AU2025287414A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514589A5 (cg-RX-API-DMAC10.html) | ||
| ES2542868T3 (es) | Terapia de combinación para el tratamiento de diabetes asociada con la obesidad | |
| US11033543B2 (en) | Methods of providing weight loss therapy in patients with major depression | |
| ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
| JP2018514589A (ja) | カンナビノイドとｎ−アシルエタノールアミンの組み合わせ | |
| EP3236960B1 (en) | Fluralaner for use in the treatment of demodicosis | |
| CA2973698A1 (en) | Compositions and methods for inhibiting fungal infections | |
| KR20190080875A (ko) | 모발 성장 자극을 위한 알파-케토부티레이트, 알파-케토글루타레이트, 및 2-하이드록시부티레이트 | |
| JP2004516257A (ja) | 糖尿病性神経障害の治療に対する組成物及びその方法 | |
| AU2019299213A1 (en) | Cannabidiol combination compositions | |
| CN101472583A (zh) | 改善患有肾功能受损的个体的利尿的方法 | |
| WO2021207325A1 (en) | Natural extract and their components for use in mitigating acute respiratory distress syndrome | |
| CN117177743A (zh) | 包含依维莫司和安森司群的组合 | |
| JP2014533692A (ja) | 虚血による神経細胞障害を低減するためのアポエクオリン | |
| Déléaval et al. | Harmless herbs? A case report of acquired long QT syndrome and torsades de pointes in a patient taking herbal supplements | |
| US20220288024A1 (en) | Methods of treating bacterial infections | |
| EA022711B1 (ru) | Комбинация дибромида 1,12-додекаметилен-бис-[4-метил-5-(2-гидроксиэтил)тиазолия] и артесуната для лечения тяжелой формы малярии | |
| EP4236931B1 (en) | Compositions comprising tetrahydrocannabinol for treating acute respiratory failure and/or acute respiratory distress syndrome | |
| US20190224208A1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| US20060211672A1 (en) | Use of estrogen receptor-beta selective agonists for radiation-or chemotherapy-induced mucositis and radiation cystitis | |
| CN110693903B (zh) | 一种治疗急性单核细胞白血病的药物及三氧化二砷和双氢青蒿素的应用 | |
| US20230263812A1 (en) | Compositions and Methods for Treating COVID-19 and/or Acute Respiratory Failure and/or Acute Respiratory Distress Syndrome Using Tetrahydrocannabinol and Compositions Including Same | |
| AU726664B2 (en) | Method for treating and preventing neurodegenerative disorders by administering a thiazolidinone | |
| CN112641765B (zh) | 丙泊酚的抗疲劳制药用途 | |
| WO2018129463A1 (en) | Co-administration of minocycline and colistin to reduce acute kidney injury |